BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31085953)

  • 1. Mechanistic Target of Rapamycin Pathway in Epileptic Disorders.
    Kim JK; Lee JH
    J Korean Neurosurg Soc; 2019 May; 62(3):272-287. PubMed ID: 31085953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epilepsy in the mTORopathies: opportunities for precision medicine.
    Moloney PB; Cavalleri GL; Delanty N
    Brain Commun; 2021; 3(4):fcab222. PubMed ID: 34632383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
    Jeong A; Wong M
    J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.
    Lim JS; Kim WI; Kang HC; Kim SH; Park AH; Park EK; Cho YW; Kim S; Kim HM; Kim JA; Kim J; Rhee H; Kang SG; Kim HD; Kim D; Kim DS; Lee JH
    Nat Med; 2015 Apr; 21(4):395-400. PubMed ID: 25799227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
    Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
    Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy.
    Marsan E; Baulac S
    Neuropathol Appl Neurobiol; 2018 Feb; 44(1):6-17. PubMed ID: 29359340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Somatic Mutations in Epileptic Disorders.
    Koh HY; Lee JH
    Mol Cells; 2018 Oct; 41(10):881-888. PubMed ID: 30352490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia.
    Weckhuysen S; Marsan E; Lambrecq V; Marchal C; Morin-Brureau M; An-Gourfinkel I; Baulac M; Fohlen M; Kallay Zetchi C; Seeck M; de la Grange P; Dermaut B; Meurs A; Thomas P; Chassoux F; Leguern E; Picard F; Baulac S
    Epilepsia; 2016 Jun; 57(6):994-1003. PubMed ID: 27173016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
    McDaniel SS; Wong M
    Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy.
    Kim JK; Cho J; Kim SH; Kang HC; Kim DS; Kim VN; Lee JH
    J Clin Invest; 2019 Oct; 129(10):4207-4223. PubMed ID: 31483294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR signaling pathway genes in focal epilepsies.
    Baulac S
    Prog Brain Res; 2016; 226():61-79. PubMed ID: 27323939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
    Citraro R; Leo A; Constanti A; Russo E; De Sarro G
    Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies.
    Nguyen LH; Bordey A
    Front Neuroanat; 2021; 15():664695. PubMed ID: 33897381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain somatic mutations in MTOR leading to focal cortical dysplasia.
    Lim JS; Lee JH
    BMB Rep; 2016 Feb; 49(2):71-2. PubMed ID: 26779999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline and somatic mutations in the
    Møller RS; Weckhuysen S; Chipaux M; Marsan E; Taly V; Bebin EM; Hiatt SM; Prokop JW; Bowling KM; Mei D; Conti V; de la Grange P; Ferrand-Sorbets S; Dorfmüller G; Lambrecq V; Larsen LH; Leguern E; Guerrini R; Rubboli G; Cooper GM; Baulac S
    Neurol Genet; 2016 Dec; 2(6):e118. PubMed ID: 27830187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
    Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
    Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of brain somatic mutations in focal cortical dysplasia during epilepsy presurgical workup.
    Checri R; Chipaux M; Ferrand-Sorbets S; Raffo E; Bulteau C; Rosenberg SD; Doladilhe M; Dorfmüller G; Adle-Biassette H; Baldassari S; Baulac S
    Brain Commun; 2023; 5(3):fcad174. PubMed ID: 37324239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic target of rapamycin (mTOR) signaling in status epilepticus.
    Crino PB
    Epilepsy Behav; 2019 Dec; 101(Pt B):106550. PubMed ID: 31732331
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.